Research Nester released a report titled “Intravenous Immunoglobulin (IVIg)  Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global intravenous immunoglobulin (IVIg) market in terms of market segmentation by immunoglobulins, by application, by end user and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The market for intravenous immunoglobulin (IVIg) is anticipated to witness a CAGR of around 7.4% during the forecast period, i.e., 2019-2027. The market is segmented by immunoglobulins, by application, by end user and by region, out of which, the application segment is further segmented into chronic lymphocytic lymphoma, Kawasaki disease, inflammatory demyelinating disorders, immune thrombocytopenia, Guillain-Barre syndrome and others. The market is segmented on the basis of end user into hospitals, clinics, home care and others, out of which, the hospital segment is anticipated to hold the largest share in the global intravenous immunoglobulin (IVIg) market on account of growing demand for better quality healthcare treatments and services along with rising expenditure on healthcare.

The market in North America is estimated to hold the largest share in the market as a result of developed healthcare infrastructure as well as the presence of key market players in the region. The increasing demand for improved treatment methods and rising prevalence of immune deficiency disorders in the region are anticipated to increase the market growth. Further, the market in Asia-Pacific region is anticipated to grow at the highest rate during the forecast period as a result of growing healthcare infrastructure and developments in the region, mainly in countries such as China, Japan and India.

Increasing Administration of IVIg Therapy for Autoimmune Disorders to Propel the Market Growth

The factors affecting the immune system might include genetic factors as well as pathogens from the external environment. The prevention and cure of autoimmune disorders resulting from exposure to these factors requires intravenous immunoglobulin therapy. This is a major factor estimated to result in the growth of the market in the upcoming years. However, the various side-effects of IVIg treatment including back pain, nausea, headache and chills are anticipated to restrict the market growth.

This report also provides the existing competitive scenario of some of the key players of the global intravenous immunoglobulin (IVIg) market which includes company profiling of Baxter International (BAX), Abeona Therapeutics Inc. (ABEO), China Biologic Products Holdings, Grifols, S.A Biotest AG, CSL Behring (CSL), Octapharma, Kedrion S.p.A, Shire, ADMA Biologics, Inc. (ADMA) and Hualan Biological Engineering Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global intravenous immunoglobulin (IVIg) market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.